Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 243.19M P/E - EPS this Y -16.70% Ern Qtrly Grth -
Income -46.88M Forward P/E -45.89 EPS next Y -9.20% 50D Avg Chg -3.00%
Sales 105.48k PEG - EPS past 5Y - 200D Avg Chg 29.00%
Dividend N/A Price/Book 2.35 EPS next 5Y - 52W High Chg -43.00%
Recommedations 1.60 Quick Ratio 2.05 Shares Outstanding 58.88M 52W Low Chg 163.00%
Insider Own 7.34% ROA -21.98% Shares Float 48.83M Beta 1.58
Inst Own 22.58% ROE -45.34% Shares Shorted/Prior 161.06K/227.58K Price 4.13
Gross Margin - Profit Margin - Avg. Volume 251,790 Target Price 8.01
Oper. Margin -242,200.12% Earnings Date Aug 8 Volume 238,608 Change -1.20%
About InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

InflaRx N.V. News
12/24/24 US Penny Stocks To Watch In December 2024
12/20/24 InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
11/19/24 Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?
11/15/24 InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
11/13/24 Prenetics Global And 2 Other US Penny Stocks To Watch
11/12/24 InflaRx Reports Q3 2024 Financial Results and Progress
11/10/24 We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
11/09/24 InflaRx expects cash to fund operations into 2026
11/08/24 InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates
11/08/24 InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
10/31/24 InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
09/25/24 InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
09/03/24 InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
06:30 AM InflaRx Announces Participation in September Investor Events
08/08/24 InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
08/08/24 InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
08/01/24 InflaRx to Report Second Quarter 2024 Results on August 8, 2024
07/30/24 InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
06/24/24 Sector Update: Health Care Stocks Rise in Late Afternoon Trading
06/24/24 InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
IFRX Chatroom

User Image dogDazeSummer Posted - 9 hours ago

@MrCompassion by end of FY2025, we may have revenue via a Roche ($RHHBY / $IFRX) InflaRx “cute little life saving kit”. Maybe some news leakage from BARDA & 904. Much like investors are prepping today 3-6 months out - at end of 2025, there will be some FOMO. My communication suggest some level of FOMO —even now

User Image investorfromrussia Posted - 13 hours ago

$IFRX 4.3

User Image dogDazeSummer Posted - 15 hours ago

$IFRX Anyone down for Friendly wager? Closest target for 12 months from today? By that time, we will have clarity on several open items: PG data / study EMA approval EMA partner assuming we get approved in 2-3 weeks INF904 by summer Best guess on 12/31/25 closing price ?

User Image TheGhostOfEd Posted - 16 hours ago

$IFRX Looking good.....need to take out that 2.82 interim high

User Image Ooil Posted - 19 hours ago

@MacGyverBud 2025?

User Image MacGyverBud Posted - 19 hours ago

$IFRX $XBI $NBI “Time to jump in and get ready for liftoff! 🚀 Listen up, folks – those who invest now will be reaping the rewards in the coming year. The signals are clear, the markets are primed, and the opportunities are right in front of you. Don’t miss out on this chance! Mark my words: Invest now and thank me later. 2024 is going to be breathtaking – get in before it’s too late! 💸”

User Image createrrit Posted - 19 hours ago

$IFRX for those of us that invest / trade quantum stocks, it’s so hard to come to terms with the idea that those stocks and IFRX with its glacial pace are both part of the same stock market, lol

User Image FlowerInTheCellar Posted - 1 day ago

$IFRX https://pubmed.ncbi.nlm.nih.gov/39720859/ Expert opinion: New therapeutics such as interleukin-36 inhibitor and complement component C5a inhibitor specifically target key pathways in the pathogenesis of PG, have shown promise, and may greatly benefit patients with PG who still lack FDA-approved treatment. In addition to systemic therapy, local wound care and pain management should be performed concurrently to achieve successful wound healing. Keywords: vilobelimab

User Image marvessa Posted - 2 days ago

$IFRX First step for me is 20 Cent up to be back in Green

User Image Barkingdogs Posted - 2 days ago

$IFRX you wanna have a happy new year??? Buy this before the 67 day limit

User Image MacGyverBud Posted - 2 days ago

$IFRX $XBI $NBI This stock is about to take off – the perfect time to jump in! 🚀 Take a close look at the latest developments: strong fundamentals, groundbreaking projects, and clear upward momentum. All signs point to a massive breakout on the horizon. The momentum is building, and the market potential is huge – this could be the next rocket to the moon. Hesitate now, and you’ll be left watching from the sidelines. Don’t miss this opportunity – the time to act is now! 💥

User Image dntlkmeflkoff Posted - 2 days ago

$IFRX no one believes you you pce of shyt levi --people like you make me want to puke --crawl back in your hole and shut up---if new people listened to you they would be up almost $2.00 a share ---just cause your a stupid azz ---rest of us averaged down where we could and are quite profitable --you on the other hand --enjoy your coal in your stocking and your losses--dumbazz

User Image levystrauss Posted - 2 days ago

$IFRX Bearish does not mean being short imbecile

User Image dntlkmeflkoff Posted - 2 days ago

$IFRX Crawl back in your hole Levi --you miserable short loser --dont listen tothe moron who short and got caught---do your own homework

User Image levystrauss Posted - 3 days ago

$IFRX Powering a rocket is easy too, or talking about things that have nothing to do with IFRX like compassion does for hours and hours, but the reality is still negative with a hint of optimism a few weeks after approval in Europe with many points of questions and doubts

User Image levystrauss Posted - 3 days ago

$IFRX The opinion can only still be negative on this stock which we have had in our portfolio for years at a great loss. Only a few months remain before an OFFERING and dilution, time is running out

User Image levystrauss Posted - 3 days ago

$IFRX Optimal! Let's hope for a rally at the end of the year. However, Niels still doesn't communicate anything important, neither contracts nor agreements and this is not good

User Image TigerRocket Posted - 3 days ago

$IFRX Happy Birthday, Niels! May you be blessed with many more!

User Image TheGhostOfEd Posted - 3 days ago

$IFRX https://www.dermatologytimes.com/view/don-t-under-treat-hidradenitis-suppurativa-a-roadmap-from-hesitant-to-confident IFRX: aiming to provide some hope for patients suffering with this disease.

User Image TheGhostOfEd Posted - 3 days ago

$IFRX Up 30% in 2 days off that intraday $1.93 flush....me likey

User Image cielo1 Posted - 3 days ago

$IFRX loving every minute of it, all noise under $15. Kindest regards to all!!

User Image Noble98 Posted - 3 days ago

$IFRX Wouldn’t want to go into Xmas without shares. 😉 🤞🤞🎅🧑‍🎄🎄

User Image mconnell Posted - 3 days ago

$IFRX

User Image Barkingdogs Posted - 3 days ago

$IFRX

User Image Barkingdogs Posted - 3 days ago

$IFRX let's just put it out there 12-20 HC Wainwright says buy I say buy all you can!! At $20 this a 1 billion dollar deal At $50 it's a 5 billion dollar deal Amgen ..what did they buy for 5 million??? Do your homework Know what you own someone said 🤑🤑🤑🤑🤑🤑 $20 minimum

User Image Barkingdogs Posted - 3 days ago

$IFRX 6 month gain is 52% Buy a stock that is going up! 🚀 Buy. Hold. Buy

User Image mconnell Posted - 3 days ago

$IFRX HIGHtex - I hope you didn't get stop loss raided and still have to 20K shares

User Image createrrit Posted - 3 days ago

$IFRX nice price action the last few days, now if we could get a little volume to light the fuse…

User Image mconnell Posted - 3 days ago

$IFRX March it to $2.75

User Image dogDazeSummer Posted - 3 days ago

$IFRX today is good example of why a stock “back and filling” is good - despite it feeling painful at the time. They took it to $2.7 and some ppl put stops at $2 a reasonable idea 25% below then current levels. But it doesn’t work in on thin biotech names. Every stop loss was cleared & triggered and buyer walk away with a free ride on 50k+ shares & now no overhead resistance until $2.5-$2.75 or more. Same thing happened at $1.50.

Analyst Ratings
HC Wainwright & Co. Buy Sep 25, 24
HC Wainwright & Co. Buy Jun 24, 24
HC Wainwright & Co. Buy Jun 6, 24
HC Wainwright & Co. Buy May 9, 24
HC Wainwright & Co. Buy Mar 22, 24
HC Wainwright & Co. Buy Jan 25, 24
Raymond James Strong Buy Nov 2, 23
HC Wainwright & Co. Buy Sep 12, 23
HC Wainwright & Co. Buy Aug 31, 23